Product image of Lafene (Fentanyl) supplied by GNH India

Lafene

Active Ingredient:
Fentanyl
Origin:
EU

Lafene (Fentanyl)

Fentanyl, the active ingredient in Lafene, is an opioid analgesic presented as a transdermal patch for transdermal use. It provides continuous systemic delivery to manage severe chronic pain, cancer‑related pain, and other conditions that require ongoing opioid therapy in adult patients.

GNH India supplies Lafene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with rigorous quality assurance and regulatory compliance.

Manufacturer / TM Owner

Lavipharm S.A

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lafene (fentanyl) is indicated for conditions requiring potent, continuous opioid analgesia.

  • Severe chronic pain: provides long‑acting relief for patients with persistent severe pain not adequately controlled by other analgesics.
  • Cancer‑related pain: delivers steady opioid levels to manage moderate to severe pain associated with malignant disease.
  • Pain requiring continuous opioid therapy: offers a non‑oral route for patients who need around‑the‑clock opioid coverage.

How It Works

  • Fentanyl is a synthetic opioid that acts as a high‑affinity agonist at the μ‑opioid receptors in the central nervous system. Binding to these receptors inhibits transmission of nociceptive signals and alters pain perception, producing potent analgesia. The transdermal patch releases fentanyl through the skin, maintaining steady plasma concentrations over several days.

Side Effects

Lafene may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate feeling of sickness.
  • Constipation: reduced bowel movements.
  • Drowsiness: increased sleepiness or fatigue.
  • Skin irritation at patch site: redness, itching, or rash.

Serious or Rare Side Effects

  • Respiratory depression: slowed or shallow breathing that can be life‑threatening.
  • Severe hypotension: marked drop in blood pressure.
  • Opioid dependence or withdrawal: signs of addiction or withdrawal on discontinuation.

Precautions & Warnings

When prescribing Lafene, clinicians should observe several safety precautions to minimize risks.

  • Patient selection: assess opioid tolerance and risk of respiratory depression before initiating therapy.
  • Dose titration: start with the lowest effective dose and adjust cautiously under medical supervision.
  • Concomitant CNS depressants: avoid or closely monitor use with benzodiazepines, alcohol, or other sedatives.
  • Pregnancy and lactation: use only if benefits outweigh potential fetal or neonatal risks.
  • Monitoring: regularly evaluate pain control, signs of overdose, and skin condition at the patch site.
  • Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Avoid Interactions

Lafene can interact with other medicines, altering its analgesic effect or increasing adverse events.

Major Interactions (Avoid)

  • Respiratory depressants: concurrent use with benzodiazepines or barbiturates may cause profound respiratory depression.
  • CYP3A4 inhibitors: strong inhibitors such as ketoconazole or clarithromycin can raise fentanyl plasma levels, increasing toxicity risk.
  • MAO inhibitors: combined use may precipitate severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers: agents like rifampin may reduce fentanyl concentrations, diminishing analgesia.
  • CNS stimulants: drugs that counteract sedation (e.g., stimulants) may mask opioid effects.
  • Alcohol: moderate to heavy intake can enhance central nervous system depression.

Frequently Asked Questions

Lafene is a fentanyl transdermal patch prescribed for the management of severe chronic pain, cancer‑related pain, and other conditions that require continuous opioid therapy. It provides steady systemic analgesia over several days, reducing the need for frequent dosing.

Fentanyl works by binding with high affinity to μ‑opioid receptors in the brain and spinal cord. This activation blocks the transmission of pain signals and modifies the perception of pain, resulting in potent and long‑lasting analgesia.

The appropriate dose of Lafene is determined by the prescribing clinician based on the patient’s pain severity, opioid tolerance, and overall clinical condition. The prescriber selects the patch strength and replacement interval that best matches the individual’s therapeutic needs.

Fentanyl, including Lafene, should be used during pregnancy or lactation only when the potential benefit justifies the potential risk to the fetus or infant. Clinicians generally avoid opioid therapy in these settings unless no safer alternatives are available.

To order Lafene, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lafene delivers fentanyl, a highly potent synthetic opioid, whereas other patches may contain buprenorphine or morphine. Fentanyl’s high lipid solubility allows efficient transdermal absorption, offering rapid onset and consistent plasma levels, but it also requires careful monitoring for respiratory depression.

Store Lafene patches at room temperature, below 25 °C, in their original packaging. Keep them away from moisture, direct sunlight, and heat sources. Do not expose the patches to extreme temperatures or puncture them before use.

Lafene is applied to clean, dry, hair‑free skin on the upper torso or upper arm. The patch is worn for the prescribed duration, typically several days, after which it is removed and replaced with a new patch at a different site to avoid skin irritation.

The most serious risks associated with Lafene include respiratory depression, severe hypotension, and the potential for opioid dependence or withdrawal. Patients should be monitored for signs of shallow breathing, extreme drowsiness, or sudden drops in blood pressure.

Lafene is contraindicated in patients with known hypersensitivity to fentanyl or other opioid analgesics, those with severe respiratory insufficiency, acute or severe asthma, and individuals who are not opioid‑tolerant. It should also be avoided in patients taking MAO inhibitors within 14 days.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.